Bioequivalence of a 68 mg Etonogestrel Subdermal Implant Compared with Reference Product in Healthy Premenopausal, Non‑Pregnant Women

The primary objective of this study is to evaluate the **bioequivalence** of an Etonogestrel 68 mg implant in healthy pre-menopausal, non-pregnant female participants. This is clinically relevant as it aims to ensure that the implant provides consistent and reliable hormonal delivery, which is crucial for its effectiveness as a contraceptive method. The study does not involve participants with any specific medical condition, focusing instead on a healthy population to assess the implant's performance under standard physiological conditions.

The clinical trial involves a **study population** consisting exclusively of female participants, with an age range categorized as adults. The trial does not focus on any specific **medical condition**, as indicated by the absence of a targeted condition. The sponsor has not provided information regarding the total number of participants involved in the study. The trial population selection criteria include a focus on a vulnerable population, although specific lifestyle considerations such as diet, physical activity, or habits have not been detailed. The sponsor has not disclosed any principal inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the **bioequivalence** of an Etonogestrel 68 mg implant in healthy pre-menopausal, non-pregnant female participants. This study is a Phase 2 trial, categorized as a bioequivalence study, and does not involve any specific medical condition. The trial is expected to commence recruitment on June 6, 2025, and is estimated to conclude by November 15, 2025. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This visit is crucial for confirming that participants meet the study's inclusion criteria and do not fall under any exclusion criteria. Following the screening, participants will be randomized into different study groups. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health and the implant's effects. These visits are essential for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments will be conducted, and the implant will be removed if necessary.

The expected duration of participant involvement in the study is approximately five months, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience adverse effects, withdraw consent, or fail to comply with the study protocol. The trial's design and procedures are structured to ensure participant safety and the integrity of the data collected.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Additionally, details about drug administration, dosing schedules, and participant compliance monitoring are not included in the source data. As such, no further information can be offered regarding the substances or treatments involved in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on June 6, 2025, with an estimated completion date of November 15, 2025. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the therapeutic impact of the intervention over the course of the study period. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy outcomes.